DBV Technologies is a global clinical stage biopharmaceutical company focused on advancing epicutaneous immunotherapy using its innovative VIASKIN® patch technology to treat food allergies and other immunological diseases
DBV Technologies is a global clinical stage biopharmaceutical company focused on advancing epicutaneous immunotherapy using its innovative VIASKIN® patch technology to treat food allergies and other immunological diseases.
The top three firms on F4's Biotech & Life Sciences investor list.